A wound sealing powder, method of making a wound sealing powder, and method of using a wound sealing powder to reduce blood flow from a wound are provided. Specifically, the wound sealing powder utilizes a particulate powder material of an effective amount of an insoluble cation exchange material wherein the majority of the particles in the powder have particle sizes of less than approximately 48 microns.

A hemostatic compound is provided. The hemostatic compound comprises molecular sieves and a fiber. The molecular sieves are independently dispersed on a fiber surface of the fiber without agglomeration and directly contact the fiber surface. A first surface of the molecular sieve contacted with the fiber is defined as an inner surface, and a second surface of the molecular sieve uncontacted with the fiber is defined as an outer surface. The molecular sieve forms a growth-matched coupling with the fiber on the inner surface, and the growth-matched coupling refers to that a plurality of molecular sieve microparticles grow to match the fiber surface to form a tightly-coupled coupling interface that matches the fiber surface.

A bioresorbable haemostatic foam sponge for adhering to a wound. The sponge has a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements. Also disclosed are methods for forming the haemostatic sponge and methods of using the sponge.

A wound or access location dressing device can be used with a transcutaneous medical device such as a cannula, a catheter, or other transcutaneous interventional device. The dressing device is formed at least partially of a flexible hydrophillic polyurethane matrix, an antimicrobial agent contained within or coupled to the matrix, and a hemostatic agent contained within or coupled to the matrix.

The present invention is directed to an expandable compression bandage. The expandable compression bandage includes: an adhesive bandage part; and a pressing part including a solvent storage part and an expandable part. The solvent storage part is configured to be attached to a part of an adhesive surface of the adhesive bandage part and to store a swelling solvent, and the expandable part is configured to be disposed beneath the solvent storage part. The expandable part is swollen and expanded when the swelling solvent stored in the solvent storage part is absorbed thereinto.

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting pre-mixed fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

An assembly for use in sheathless transradial procedures includes a wristband that is adapted to be adjustably securable about a patient's wrist proximate an access point. A shaped member is secured relative to a midpoint of the wristband and is adapted to provide pressure proximate the access point. A hemostatic valve extends through the shaped member and is adapted to permit one or more elongate medical devices to extend therethrough.

A hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device includes: a release layer, the release layer in contact with a hemostatic flexible foam section, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the backside of the structural foam layer.

A knit hemostatic bandage provided herein can include a continuous rayon fiber and a continuous glass fiber. The knit hemostatic bandage can have a gauge of between 10 and 30 stitches per inch. The knit hemostatic bandage can have a Young's modulus of elasticity of less than 50 MPa.

The invention relates to a unit for hemostasis. The unit is configured to be directly applied to a bleeding wound and comprises an envelope enclosing an inner space as well as an effective amount of a hemostatic material disposed within the inner space. Furthermore, the invention relates to an arrangement of two or more such units for hemostasis, the units being coupled to each other. Moreover, the invention relates to a method for producing an arrangement of units for hemostasis. In accordance with the method, an effective amount of a hemostatic material is disposed within an interior region of a starting material, and neck regions are formed on both sides of the charge so as to form an envelope enclosing the charge.